Exposure of MCF-7 breast cancer cells to electromagnetic fields up-regulates the plasminogen activator system

International Journal of Gynecological Cancer

Volumn 19, Issue 3, 2009, Pages 334-338

  Girgert, Rainer ^a   Emons, Günter ^a   Hanf, Volker ^b   Gründker, Carsten ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b KLINIKUM FÜRTH   (Germany)

Author keywords

Breast cancer; Electromagnetic fields; Gene expression; Metastasis; Plasminogen activator

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CELL STRAIN MCF 7; DOWN REGULATION; ELECTRICITY; ELECTROMAGNETIC FIELD; ENVIRONMENTAL EXPOSURE; GENE EXPRESSION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

BREAST NEOPLASMS; ELECTROMAGNETIC FIELDS; FEMALE; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; UP-REGULATION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 68149168060     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e31819f53ec     Document Type: Article

References (28)

1. Schüz J., Grigat JP, Brinkmann K., et al. Residential magnetic fields as a risk factor for childhood acute leukaemia: results from a German population-based case-control study. Int J Cancer. 2001;91:728-735.
2. Wertheimer N., Leeper E. Adult cancer related to electrical wires near the home. Int J Epidemiol. 1982;11:345-355.
3. Feychting M., Forssen U., Rutqvist LE, et al. Magnetic fields and breast cancer in Swedish adults residing near high-voltage power lines. Epidemiol. 1998;9:392-397.
4. Labreche F., Goldberg MS, Valois MF, et al. Occupational exposures to extremely low frequency magnetic fields and postmenopausal breast cancer. Am J Ind Med. 2003;44:643-652.
5. van Wijngaarden E., Nylander-French LA, Millikan RC, et al. Population-based case-control study of occupational exposure to electromagnetic fields and breast cancer. Ann Epidemiol. 2001;11:297-303.
6. Verkasalo PK, Pukkala E., Kaprio J., et al. Magnetic fields of high voltage power lines and risk of cancer in Finnish adults: nationwide cohort study. BMJ. 1996;313:1047-1051.
7. Li CY, Theriault G., Lin RS. Residential exposure to 60-Hertz magnetic fields and adult cancers in Taiwan. Epidemiol. 1997;8:25-30.
8. Thun-Battersby S., Mevissen M., Löscher W. Exposure of Sprague-Dawley rats to a 50-Hertz, 100-microTesla magnetic field for 27 weeks facilitates mammary tumorigenesis in the 7, 12-dimethylbenz[a]-anthracene model of breast cancer. Cancer Res. 1999;59:3627-3633.
9. Anderson LE, Morris JE, Sasser LB, et al. Effects of 50-or 60-Hertz, 100 microT magnetic field exposure in the DMBA mammary cancer model in Sprague-Dawley rats: possible explanations for different results from two laboratories. Environ Health Perspect. 2000;108:797-802.
10. Mevissen M., Kietzmann M., Löscher W. In vivo exposure of rats to a weak alternating magnetic field increases ornithine decarboxylase activity in the mammary gland by a similar extent as the carcinogen DMBA. Cancer Lett. 1995;90:207-214.
11. Di Carlo A., White N., Guo F., et al. Chronic electromagnetic field exposure decreases HSP70 levels and lowers cytoprotection. J. Cell. Biochem. 2002;84:447-454.
12. Lin H., Head M., Blank M., et al. Myc-mediated transactivation of HSP70 expression following exposure to magnetic fields. J Cell Biochem. 1998;69:181-188.
13. Morehouse CA, Owen RD. Exposure to low-frequency electromagnetic fields does not alter HSP70 expression or HSF-HSE binding in HL60 cells. Radiat Res. 2000;153:658-662.
14. Shi B., Farboud B., Nuccitelli R., et al. Power-line frequency electromagnetic fields do not induce changes in phosphorylation, localization, or expression of the 27-kilodalton heat shock protein in human keratinocytes. Environ Health Perspect. 2003;111:281-288.
15. Girgert R., Schimming H., Körner W., et al. Induction of tamoxifen resistance in breast cancer cells by ELF electromagnetic fields. Biochem Biophys Res Commun. 2005;336:1144-1149.
16. Girgert R., Gründker C., Emons G., et al. Induction of tamoxifen resistance in breast cancer cells by electromagnetic fields depends on altered expression of estrogen receptor cofactors. Bioelectromagnetics. 2008;29:169-176.
17. Cristofanilli M. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Semin Oncol. 2006;33:S9-S14.
18. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12:895-904.
19. Nugoli M., Chuchana P., Vendrell J., et al. Genetic variability in MCF-7 sublines: evidence of rapid genomic and RNA expression profile modifications. BMC Cancer. 2003;3:13-18.
20. Osborne CK, Hobbs K., Trent JM. Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res Treat. 1987;9:111-121.
21. Shiba E., Kim SJ, Taguchi T., et al. A prospective study on the prognostic significance of urokinase-type plasminogen activator levels in breast cancer tissue. J Cancer Res Clin Oncol. 1997;123:555-559.
22. Foekens JA, Peters HA, Look MP, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 2000;60:636-643.
23. Decock J., Paridaens R., Cufer T. Proteases and metastasis: clinical relevance nowadays? Curr Opin Oncol. 2005;17:545-550.
24. de Witte JH, Foekens JA, Brunner N., et al. Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours. Br J Cancer. 2001;85:85-92.
25. Hemsen A., Riethdorf L., Brunner N., et al. Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells. Int J Cancer. 2003;107:903-909.
26. Chappuis PO, Dieterich B., Sciretta V., et al. Functional evaluation of plasmin formation in primary breast cancer. J Clin Oncol. 2001;19:2731-2738.
27. de Witte JH, Sweep CG, Klijn JG, et al. Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer. Br J Cancer. 1999;80:286-294.
28. Harbeck N., Kates RE, Schmitt M., et al. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer. 2004;5:348-352.